Abstract: AbbVie submitted a new drug application for Elagolix to the FDA on September 6, 2017, and received the FDA's priority review in more than a month. Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist, has the very good curative effect on endometriosis for menstrual pelvic pain. Compared with and previously known as GnRH agonists, Elagolix has high oral bioavailability, and avoid the pain caused by injection and allergic reaction, and increased patient compliance. Currently, the drug has been delayed to the FDA in the third quarter of 2018 regarding the supplementary data on liver injury. The principle of adverse reactions to liver injury is not clear. Elagolix hopes to be a new oral GnRH antagonist agent in the treatment of endometriosis, and we will continue to pay attention to the follow-up research progress.

Key words: Elagolix, Endometriosis, Gonadotropin-releasing hormone